Position in SVTR
Snapshot 2026-10-26- Startup SignalsTop 50%↓1
- Life SciencesTop 50%
- BCI#6of 18
About
Axoft, founded in 2021 in Cambridge, Massachusetts, USA, develops implantable brain-computer interfaces using biomimetic materials, employing flexible neuroelectronic materials to achieve high-resolution neural recording and stimulation.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-05Series A$55M
Investors · Alumni Ventures, C.P. Group Innovation, Stanford President's Fund, Gaorong Ventures, Hillhouse InvestmentSource · SVTR Weekly #155 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Axoft
Implantable brain-computer interfaces using biomimetic materials, with flexible neural electronics for high-resolution neural recording and stimulation
Series A · $60M · 2026-05
$60M
United States
BusinessLatest roundTotal raisedDate- Echo Neurotechnologies
Brain-computer interfaces that let patients with severe disabilities control devices with their thoughts via implanted electrodes
Series A · $50M · 2025-02
$50M - Neurable
Brain-computer interface technology integrated into everyday devices such as headphones
Series A · $48M · 2025-12
$48M - Coherence Neuro
Closed-loop brain-computer interface system SOMA, using a wireless implant to decode tumor electrical signals in real time and deliver personalized electrical stimulation to treat brain tumors and other cancers
Series A · 2026-10
—
China
BusinessLatest roundTotal raisedDate- SiClink
Founded in December 2025, SiClink is an implantable brain-computer interface company founded by ShanghaiTech University researcher Dr. He Fei. It develops semiconductor hollow flexible neural electrodes and a proprietary saline-based stiffness-modulation minimally invasive implantation process to build high-bandwidth, low-latency, long-term stable bidirectional brain-machine interfaces, starting with visual reconstruction.
— - StairMed
Developer of implantable brain-computer interface systems
Strategic · $153M · 2026-03
$153M - Qiangnao
Non-invasive brain-computer interfaces and intelligent bionic prostheses
Series D+ · $20M · 2025-11
$20M
Europe
BusinessLatest roundTotal raisedDate- Neurosoft Bioelectronics
Flexible, stretchable, non-penetrating brain-computer interfaces and neural electrodes to record/stimulate brain-surface activity
Seed · $20M · 2026-05
$20M - InBrain Neuroelectronics
Graphene-based brain-computer interface technology for neurological disorders such as Parkinson's disease.
Series B · $50M · 2024-11
$50M - MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation, on-chip processing and wireless transmission, for BCI and active implant makers
Undisclosed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDate- 脑思科技
Brain-computer interface electrodes and neural decoding systems
Angel · $10M · 2026-05
$10M - Brain.space
Non-invasive brain monitoring platform with real-time neural data analysis
Series A · $11M · 2025-03
$11M - Vital Biosciences
Diagnostic technology developing the "revolutionary" blood test VitalOne
Undisclosed · $48M · 2023-07
$48M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 26 at a nearby stage · 36 in US East Coast
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 31 in US East Coast
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in US East Coast
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in US East Coast
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in US East Coast
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in US East Coast
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.